Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company engaged in the development of peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The Company has a diverse pipeline of development programs, including development of proposed products for treatment of heart failure (HF), sexual dysfunction, obesity, diabetes and metabolic syndrome. As of June 30, 2009, Palatin’s products under development included bremelanotide, a peptide melanocortin receptor, for treatment of sexual dysfunction, targeting female sexual dysfunction (FSD) and erectile dysfunction (ED) in patients non-responsive to current therapies, PL-6983, a peptide melanocortin receptor agonists, for treatment of sexual dysfunction; PL-3994, a peptide mimetic natriuretic peptide receptor A (NPRA) agonist, for treatment of HF and melanocortin receptor-based compounds for treatment of obesity and related metabolic syndrome.